IDIOPATHIC PULMONARY FIBROSIS (IPF)
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS (IPF) explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS (IPF) trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in slowing lung scarring disease
Disease control OngoingThis study tests a new oral drug called buloxibutid in 378 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Over 52 weeks, researchers compare two doses of the drug against a placebo to see if it helps maintain lung functio…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: Vicore Pharma AB • Aim: Disease control
Last updated May 17, 2026 08:03 UTC
-
Can exercise at home help lung disease patients breathe easier?
Symptom relief OngoingThis pilot study tests whether home-based or supervised online exercise programs are acceptable and helpful for people with chronic lung diseases like IPF, sarcoidosis, bronchiectasis, and asthma. About 50 participants will be randomly assigned to one of three groups: group onlin…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: NA • Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Symptom relief
Last updated May 17, 2026 08:01 UTC
-
Gene hunt: can DNA predict lung disease progression?
Knowledge-focused OngoingThis study follows 250 adults with inherited forms of pulmonary fibrosis to see how their genes influence the speed of lung decline. Participants undergo regular breathing tests and genetic analysis, but no new treatments are tested. The goal is to better understand why some peop…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated May 14, 2026 12:04 UTC
-
Massive study tracks lung disease progression in over 1,400 patients
Knowledge-focused OngoingThis study follows 1,423 adults with idiopathic pulmonary fibrosis (IPF) for up to two years to learn how the disease naturally progresses. Researchers will track events like sudden worsening, hospital stays, and deaths. The goal is to better understand IPF patterns, not to test …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC